Kornimate/medical-research-clean huggingface dataset:
suprachoroidal injection of cls-ta alone or with aflibercept in subjects with diabetic macular edema

Conditions: Diabetic Macular Edema

Summary: this study is designed to demonstrate the safety and tolerability of suprachoroidal cls-ta alone or in combination with intravitreal aflibercept in subjects with diabetic macular edema associated with diabetes mellitus.

this is a phase 1/2, multicenter, open-label study in subject with dme associated with diabetes mellitus. subjects will be screened and if eligible, will be assigned to study arm at the baseline visit (visit 1, day 0). following the baseline visit, subjects will participate in six monthly follow-up visits (visit 2-7; weeks 4-24) for safety and efficacy assessments and to determine whether additional therapy is needed based upon pre-defined criteria.

Eligibility criteria:
inclusion criteria: * men or women ≥ 18 years of age with type 1 or type 2 diabetes mellitus * dme with central involvement (\>320 microns in the central subfield on sd-oct) in the study eye * etdrs bcva letter score of 83 to 14, inclusive (snellen equivalent of 20/25 to 20/500) in the study eye exclusion criteria: * evidence of dme due to any other cause other than diabetes mellitus in the study eye * prp or focal laser photocoagulation in the study eye within 90 days of screening * intraocular pressure ≥ 22 mmhg or uncontrolled glaucoma (open angle or angle closure) in the study eye * history of any previous ophthalmic surgeries in the study eye within 90 days of screening * high risk pdr in the study eye, for whom enrollment into the study, in the principal investigator's opinion would put the eye at undue risk for vision loss * any previous treatment in the study eye with iluvien implant * previous treatment for dme in the study eye (tx naive arm only); treatment in the study eye for dme greater than 1 year prior to screening can be considered as treatment naive, at the investigator's discretion * subjects previously treated for dme cannot have been treated in the study eye with an intravitreal injection of anti-vegf or periocular corticosteroids within 90 days prior to screening (previous tx arm only) * subjects previously treated for dme cannot have been treated in the study eye with intraocular corticosteroids within 6 months prior to screening (previous tx arm only)

Keywords: diabetes mellitus diabetic retinopathy microneedle microinjection triamcinolone choroid choroid injection aflibercept suprachoroidal triamcinolone acetonide
ons in gastrointestinal cancer patients undergoing chemotherapy

Conditions: Gastrointestinal Cancer

Summary: the study hypothesizes that the addition of oral nutrition supplement concurrent chemotherapy treatment to the gi cancer patients will improve the prognosis of cancer cachexia, improve health state quality of life and increase chemotherapy tolerance

malnutrition is a major public health issue in low- and middle-income countries and forms part of the united nations 2030 agenda for sustainable development goals .cancer is a systemic disease, since even in the early stages malignancies are accompanied by homeostatic imbalance, including metabolic deregulation and increased catabolism. these abnormalities may initially seem poorly discernible in the clinic, but with disease progression they may aggravate; and may cause overt cancer-related cachexia.gi cancers show higher mortality than any other kind of cancer. in 2020, they accounted for an estimated 3.5 million deaths worldwide, with a further 5.0 million new cases diagnosed in the same year . colorectal cancer (crc) is the most common type of gi cancer, being the third most common of all organ cancers after lung and breast cancers, whereas gastric, liver, esophageal, and pancreatic cancers are ranked the fifth, sixth, eighth, and 12th most commonly diagnosed cancers, respectively

Eligibility criteria:
inclusion criteria: - gi cancer patients will be included in the study if they meet the following criteria: 1. confirmed cancer diagnosis any stage or metastatic confirmed by radiological and pathological or by clinical evaluation receiving neo/adjuvant chemotherapy treatment. 2. age above 18 years old 3. be accessible for chemotherapy treatment and follow-up 4. availability to administer oral supplements 5. eastern cooperative oncology group (ecog) performance status ≤2 6. life expectancy ≥3 months. 7. written informed consent according to the local ethics committee requirements 8. willing to fill nutrition questionnaires. 9. negative pregnancy test for pre-menopausal women before inclusion in the trial exclusion criteria: * the patients will be excluded from the study if they have the following criteria: 1. known hypersensitivity reaction to the investigational compounds or incorporated substances 2. patients who are unlikely to comply with trial requirements (eg, confusion, psychological or mood disturbances ,alcoholism) 3. pregnancy or lactating 4. medical or psychological condition which in the opinion of the investigator would not permit the patient to complete the study or sign meaningful informed consent 5. age \< 18 years 6. indication to or ongoing artificial nutrition support (totally compromised spontaneous food-intake) and incapacity or unavailability to consume ons
jinhua qinggan granules in the treatment of covid-19

Conditions: COVID-19

Summary: the clinical trial is designed to be randomized, double blind, placebo controlled, to evaluate the effectiveness and safety of jinhua qinggan granules (jhqg) on mild-category patients of covid-19 in pakistani population with the age limit of 18-75 years, at10th day comprehensive follow-up. the informed consent form must be signed by the subjects before their participation in the trial.

the course of treatment is 10 days, and the visit points are set on the 1st and 10th day, in which 10th day is follow-up. patients will be assessed by using seven-category ordinal scale and clinical signs and symptoms on 1st and 10th day. if the subject recovers and checks out within 10 days, they will be recorded once before checking out. all effectiveness and safety inspection items will be done once before the trial and once at follow-up point i.e. 10th day. in case of any new abnormality or abnormality aggravation after the treatment, should be followed up until normal or stable.

Eligibility criteria:
inclusion criteria: * 1) between the ages of 18-75 years, both male and female. * 2) confirmed coronavirus infection by real time rt-pcr. * 3) mild cases of coronavirus having main symptoms with minimum 2 grade (as mentioned in 7.1.6). * 4) the subject has signed the informed consent form; exclusion criteria: * 1) younger than 18 years or older than 75 years. * 2) patients with moderate or critical coronavirus infection confirmed by real time rt-pcr; cases meeting any of the following criteria: 1. lung lesions 2. respiratory failure and requiring mechanical ventilation 3. shock 4. with other organ failure that requires icu cares. * 3) severe primary health conditions associated with cardiovascular, cerebrovascular, pulmonary, hepatic, renal, endocrine and hematological diseases, hematopoietic system (above grade ii of cardiac function; alt \& ast are 1.5 times higher than the normal value; creatinine above the upper limit of normal value) and mental illness or serious diseases affecting their survival, such as cancer or aids; * 4) with severe cardiopulmonary dysfunction, cardiopulmonary insufficiency. * 5) subjects, who took other antiviral, antibacterial, cough relieving, expectorant and antiasthmatic drugs within 3 days prior to the visit (including β2 receptor agonists, anticholinergic agents, theophylline drugs, glucocorticoids, expectorant and chinese medicine.) * 6) allergic individuals and those who are known to be allergic to experimental drugs * 7) pregnant women, lactating women or fertile women who are ready to conceive in 3 months. * 8) subject, who has participated in the past 1 month in another clinical study. * 9) subjects who are not suitable for the clinical trial based on investigators' judgment.
a clinical study on pre-operative intervention with products during aesthetic medicine

Conditions: Skin Aging; Skin Condition; Skin Manifestations

Summary: this clinical trial aims to evaluate whether a 14-day pre-operative application of the test product (containing mlyaat-1002®, a proprietary anti-aging complex) can mitigate skin discomfort during fotona 4d laser therapy (frac3 and piano modes) by comparing clinical evaluation, skin attributes measurement and subject self-assessment.


Eligibility criteria:
inclusion criteria: * health females aged 35-60; * subjects with rough dark, loose fine lines; * no history of cosmetic allergies; * subjects are willing to use the test serum on split-face for 28 days; * subjects are willing to suffer the fotona 4d treatment (frac3 and piano modes) on the face; * subjects are willing to use the basic skincare products for 28 days, and acceptable for split-face use of the test products or the control product for 14 days; * written informed consent and portrait right consent were obtained from all participants before study entry. exclusion criteria: * anyone who is pregnant, nursing an infant, or planning a pregnancy during the study; * subjects with known allergies or sensitivities to the ingredients in any of the study products; * any symptoms of facial flushing, erythema, papules, desquamation, or edema as evaluated by a physician prior to initial screening or fotona4d pro treatment; * unhealed skin lesions; * participated in any other clinical trial within one month; * received facial skin treatments including but not limited to lasers, chemical peels, and dermal fillers within one month; * taken/injected anti-allergy medication in the past one month; * participants in other clinical trials at the same time; * any subjects that the investigator considers ineligible.
reducing suicide risk associated with weight loss

Conditions: Eating Behavior; Self Harm; Weight Loss

Summary: the purpose of this study is to examine the efficacy of an intervention aimed at promoting a healthy lifestyle and reducing risk factors associated with eating pathology, nonsuicidal self-injury, and suicidal behavior. we are also interested in assessing whether this intervention has the potential to prevent future symptoms of eating problems and self-harm urges and behaviors. the broader goal of this research is to identify factors that may help us better understand the prevention of self-harm behaviors and develop more effective treatments for these problems.

the current study was designed as a proof-of-concept study to test the association between weight suppression (ws; difference between one's highest and lowest weight) and non-suicidal self-injury (nssi). previous research has found an association between current ws and lifetime nssi and that this association was mediated by depressive symptoms and drive for thinness. the current study therefore modified an existing online cognitive dissonance-based program (the e-body project) using mixed gender content (from the body project 4 all scripts) to target posited mediators, i.e., depressive symptoms and weight and shape concerns, in a sample of individuals with ws and engagement in current nssi.

Eligibility criteria:
inclusion criteria: * age 18-65 years old * at least 5 pounds weight suppression * engaged in non-suicidal self-injury at least once in past month exclusion criteria: * indicated being "sure" of suicide attempt on eligibility screener * live outside of the united states * currently pregnant
glp-1 agonism stimulates browning of subcutaneous white adipose tissue in obesity men

Conditions: Obesity

Summary: adipose tissues, which include white adipose tissue (wat) and brown adipose tissue (bat), play an essential role in regulating whole-body energy homeostasis. excess expansion of wat due to positive energy balance and defects in thermogenic gene expression in bat are associated with obesity and various metabolic diseases. until 2009 the question of whether adult humans had bat and whether it could conceivably contribute to whole body energy usage in a meaningful way was a matter of vigorous debate. the publication of three apppers in the new england journal of medicine that demonstrated adult humans do have bat, that it can be activated, and that this activation appears to be defective in obesity reframed the debate, and revived interest in bat physiology. recent studies also reveal the presence of a subset of cells in wat that could be induced by environmental or hormonal factors to become ''brown-like'' cells, and this ''beigeing'' process has been suggested to have strong antiobesity and antidiabetic benefits. the extrapancreatic actions of glucagon-like peptide-1 (glp-1) on endothelial cells and the liver have been reported. additionally, effects of glp-1 on adipose tissue have been described. studies performed in isolated adipocytes have demonstrated that glp-1 has the ability to induce both lipogenic and lipolytic mechanisms in white adipose tissue (wat) . more recent study showed that glp-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic amp-activated protein kinase (ampk) in animal. however, there is no data clearly show that glp-1 agonism stimulates browning of subcutaneous white adipose tissue (swat) in human obesity.

individuals were treated for 10 days. biopsy for subcutaneous white adipose (1.5x1.5x1.5cm) was performed before and after 10 days treatment programme under local anesthesia. measure the brown fat characteristics of biopsy samples.the sample was immediately processed in 3 sections.one part was stored for immunohistology and western blot, the second was snap-frozen for estimation of biochemical markers, and the remainder was used to harvest small subcutaneous arteries with micro-dissection. also, the perivascular adipose tissue (pvat) was studied on the changes of morphology and possible signal pathways before and after glp-1 treatment.

Eligibility criteria:
inclusion criteria: * body mass index (bmi) \> 30 kg/m2 * men * age 20 - 30 years old exclusion criteria: * bmi \< 30 kg/m2 * diabetes * hypertension * use of medicines
effectiveness of a home rehabilitation program vs an e-health program in patients with chronic low back pain

Conditions: Low Back Pain

Summary: the main objetive of this study is to analyze the effectiveness of a home rehabilitaton program vs a e-health program. therapeutic approach will be by electroanalgesia and exercise of patients with chronic low back pain.

a double blind clinical trial will be developed in a sample of 80 subjects with chronic low back pain. patients will receive 3 weekly sessions of electroanalgesia and an exercise program for 8 weeks, for a total of 24 sessions. the aim is to analyze the effectiveness of a home rehabilitation program vs a web platform program on disability, pain, fear of movement, quality of life, resistance of the trunk flexors, lumbar mobility in flexion and muscular electrical activity.

Eligibility criteria:
inclusion criteria: * low back pain ≥ 3 months. * age between 30 and 67 years old. * score ≥ 4 points on the roland morris disability questionnaire. * not being receiving physical therapy. exclusion criteria: * presence of lumbar stenosis. * diagnosis of spondylolisthesis. * diagnosis of fibromyalgia. * treatment with corticosteroids or oral medication in recent weeks. * history of spine surgery. * contraindication of analgesic electrical therapy. * have previously received a treatment of electrical analgesia or exercise. * central or peripheral nervous system disease. * agoraphobia

Keywords: low back pain electroanalgesia exercise program randomized clinical trial
patient navigator project

Conditions: Breast Cancer; Colon Cancer

Summary: patient navigation is a supportive care intervention that addresses barriers to quality standard care by providing individualized assistance to patients and families. the nci is conducting several research programs to test the effectiveness of this approach. the expected outcomes of patient navigation through the cancer care system include: * timely, definitive diagnosis following an abnormal test * timely treatment following positive diagnosis * patient satisfaction with the diagnostic and care system experience

the goal of our local project is to provide tampa bay with a culturally appropriate patient navigator program that will decrease delay in diagnosis and delivery of cancer care in an acceptable and cost-effective manner leading to lower cancer mortality among our underserved populations. we will partner with community health centers in the tampa bay area to provide an avenue for patients who have received an abnormal screening for breast and colorectal cancer to easier pilot the course of the healthcare system. the populations served by this program will include african-americans, hispanics and rural whites who are medically underserved due to lack of insurance, documentation issues and a variety of other barriers to health care. the primary outcome to be tested with this program is the time it takes for patients with an abnormality to receive a definitive diagnosis. secondary outcomes such as patient satisfaction and cost-effectiveness will also be measured. this program occurs in three phases. in phase i, the aim is to work closely with our key community partners to conduct formative research for the development of an acceptable, appealing, and appropriate patient navigator program. the aim for phase ii is to conduct a group randomized controlled trial by having participating clinics randomly assigned to an intervention or control clinic. the outcomes from this phase in the project will be assessed through chart reviews, patient satisfaction surveys and other survey methods. in phase iii a comprehensive evaluation on the program will be produced and disseminated nationally.

Eligibility criteria:
inclusion criteria: * receive health care at one of the enrolled clinics * newly diagnosed with breast of colorectal cancer or if they have an abnormality that is suspicious for breast (breast lump, or abnormal mammogram) or colorectal cancer (abnormal colon screening test, blood in bowel movement). exclusion criteria: * persons with previous history of breast or colon cancer will be excluded from the study

Keywords: patient navigation breast cancer colon cancer questionnaire
choroidal change on octa in eyes with high myopia

Conditions: Myopia, Progressive; Choroid Disease

Summary: myopia is a global healthy concern, especially the high myopia and pathological myopia among asian populations. however, its mechanism still remains largely unclear. recent findings suggested choroidal changes might be related to the development of myopia. this study is to useoct angiography (oct-a) to investigate parapapillary choroidal microvasculature change in myopic eyes, and try to find the cause-and-effect relationship between choroidal change and the development of myopia.


Eligibility criteria:
inclusion criteria: 1. spherical equivalent measurement can be included in above 4 groups 2. willing to be followed up in the future 10 years exclusion criteria: 1. deny to sign the patient consent, or deny to be followed 2. evidence of cardiac, or diabetic, or cns disease. 3. clinically diagnosed with retinal or choroidal disease 4. glucoma 5. cataract or corneal disease that influence the quality of fundus octa image

Keywords: octa myopia choroid
examination of postdural puncture headache frequency, predisposing factors and treatment

Conditions: Postdural Puncture Headache

Summary: post-dural puncture headache (pdph) is one of the most important complications of neuraxial blocks and lumbar interventions for cerebrospinal fluid (csf) examination. it occurs due to tear in the dura mater and loss of cerebrospinal fluid (csf) after intrathecal or epidural interventions.the incidence of pdph depends on the thickness of the needle used and the type of tip. headaches are more common with thick needles than with thin needles.in our study, postdural puncture headache in patients whose surgery was planned and spinal anesthesia was applied at süleyman demirel university faculty of medicine;frequency, predisposing factors, treatment intended to examine.

different anesthesia techniques are applied to patients undergoing surgery. these are general anesthesia and regional (spinal, epidural, peripheral nerve blocks, etc.) anesthesia applications. today, regional anesthesia is the most frequently preferred anesthesia method by anesthesiologists due to its low side effects. spinal anesthesia is the temporary stopping of nerve conduction with a local anesthetic solution injected into the cerebrospinal fluid. it is one of the most commonly used regional anesthesia techniques today.important advantages of regional anesthesia include the patient's continued spontaneous breathing, preservation of oropharyngeal reflexes, continuation of analgesia in the postoperative period, early mobilization, and short hospital stay.post-dural puncture headache (pdph) is one of the most important complications of neuraxial blocks and lumbar interventions for cerebrospinal fluid (csf) examination. the incidence of pdph is significantly higher in young people than in the elderly, in women compared to men, and in pregnant women compared to the normal population.in our study, spinal anesthesia cases will be examined. patients with headache will be identified. patients' demographic data (age, height, body weight, gender, comorbidities), asa (american society of anesthesiologists) score, operation type, presence of headache etiology, needle type and diameter used, number of interventions and procedures. level, amount of local anesthetic given, adjuvant drugs added, experience of the practitioner, amount of fluid given, date and time of headache onset, treatment and procedure complications will be monitored and recorded in the form.

Eligibility criteria:
inclusion criteria: * \>18 years * asa physical status class i, ii and iii * bmi \<40 kg/m² * patients undergoing spinal anesthesia exclusion criteria: * asa physical status class \> iii * severe cardiac, respiratory, hepatic, and renal disease * refusing spinal anesthesia * history of local anesthetic allergy * localized infection at the injection site * coagulopathy * anticoagulant drugs usage * history of chronic pain (migraine, sinusitis, etc.) * alcohol and opioid addiction * psychiatric diseases * communication difficulties * vertebral or chest wall abnormalities * bmi \> 40 kg/m²
brain oxygenation and function of preterm newborns during administration of two different surfactant preparations

Conditions: Respiratory Distress Syndrome, Newborn; Respiratory Failure

Summary: the purpose of the study is to determine whether there are differences in bioelectrical function (measured by amplitude integrated electroencephalography) and brain oxygenation (measured by near infrared spectroscopy) while and after instillation of two different surfactant preparations.

patients randomized to one of the treatment groups: 1) srt with porcine preparation - poractant alfa; 2) srt with bovine preparation - beractant. continuous monitoring and simultaneous recordeding of 1) saturation (spo2) and heart rate (hr) measured with pulse oximetry, cerebral tissue oxygenation measured with near-infrared spectroscopy, amplitude-integrated electroencephalography.

Eligibility criteria:
inclusion criteria: * 26-30 gestational age * surfactant instillation exclusion criteria: * congenital heart disease * congenital central nervous disorder * congenital genetic disorders

Keywords: brain oxygenation nirs aeeg surfactant